Adaptive biotechnologies corporation (ADPT)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Dec'18
Assets
Current assets
Cash and cash equivalents

212,688

96,576

74,941

48,458

55,030

Short-term marketable securities (amortized cost of $340,952 and $479,791, respectively)

342,485

480,290

498,487

374,543

109,988

Accounts receivable, net

9,382

12,676

9,257

7,252

4,807

Inventory

10,518

9,069

8,667

8,004

7,838

Prepaid expenses and other current assets

9,573

14,079

10,004

4,044

3,055

Total current assets

584,646

612,690

601,356

442,301

180,718

Long-term assets
Property and equipment, net

24,952

60,355

46,542

22,298

19,125

Operating lease right-of-use assets

31,058

-

-

-

-

Long-term marketable securities (amortized cost of $98,847 and $105,263, respectively)

100,618

105,435

135,306

-

-

Restricted cash

2,100

2,100

2,138

5,040

100

Intangible assets, net

11,504

11,928

12,356

12,784

13,626

Goodwill

118,972

118,972

118,972

118,972

118,972

Other assets

998

784

722

-

186

Total assets

874,886

912,302

917,392

601,395

332,688

Liabilities and shareholders’ equity
Current liabilities
Accounts payable

3,895

4,453

2,421

2,944

1,793

Accrued liabilities

3,804

4,371

3,381

5,019

2,562

Accrued compensation and benefits

4,177

8,124

5,982

4,429

4,641

Current portion of deferred rent

-

371

324

1,276

1,109

Current operating lease liabilities

1,502

-

-

-

-

Current deferred revenue

64,572

60,994

61,269

61,194

12,695

Total current liabilities

77,950

78,313

73,377

74,862

22,800

Long-term liabilities
Convertible preferred stock warrant liability

-

-

-

2,602

336

Deferred rent liability, less current portion

-

6,918

6,258

5,455

6,102

Operating lease liabilities, less current portion

36,545

-

-

-

-

Financing obligation

-

36,607

23,449

-

-

Deferred revenue, less current portion

208,828

219,332

228,339

240,919

704

Other long-term liabilities

-

93

44

-

-

Total liabilities

323,323

341,263

331,467

323,838

29,942

Convertible preferred stock: $0.0001 par value, no and 93,762,517 shares authorized at December 31, 2019 and 2018, respectively; no and 92,790,094 shares issued and outstanding at December 31, 2019 and 2018, respectively; aggregate liquidation preference of $0 and $572,866 at December 31, 2019 and 2018, respectively

-

-

-

561,931

560,858

Shareholders’ equity
Common stock: $0.0001 par value, 340,000,000 shares authorized at March 31, 2020 and December 31, 2019; 126,621,829 and 125,238,142 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

12

12

12

1

1

Additional paid-in capital

945,026

935,834

930,208

46,160

37,902

Accumulated other comprehensive gain

3,313

671

572

382

-107

Accumulated deficit

-396,788

-365,478

-344,867

-330,917

-295,908

Total shareholders’ equity

551,563

571,039

585,925

-284,374

-258,112

Total liabilities and shareholders’ equity

874,886

912,302

917,392

601,395

332,688